We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top tier investors such as BB Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital and others.
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.
Tag cell populations for removal or shielding. Better, safer safe bone marrow transplants and stem cell replacement.
Developing novel inflammasome inhibitors.
Highly potent and specific therapies based on T cell receptor (TCR), targeting of solid tumors.
Platform to create compartment locked biologics for higher local retention and fast systemic degradation
A novel class of immunosuppressive therapies for autoimmune inflammatory diseases and organ transplantation